Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
ErbB Receptors
/ antagonists & inhibitors
Female
Gefitinib
/ administration & dosage
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Pemetrexed
/ administration & dosage
Progression-Free Survival
Protein Kinase Inhibitors
/ adverse effects
Quality of Life
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 01 2020
10 01 2020
Historique:
pubmed:
15
8
2019
medline:
26
6
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Standard first-line therapy for This was a phase III randomized trial in patients with advanced NSCLC harboring an Between 2016 and 2018, 350 patients were randomly assigned to Gef (n = 176) and Gef+C (n = 174). Twenty-one percent of patients had a performance status of 2, and 18% of patients had brain metastases. Median follow-up time was 17 months (range, 7 to 30 months). Radiologic response rates were 75% and 63% in the Gef+C and Gef arms, respectively ( Adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.
Identifiants
pubmed: 31411950
doi: 10.1200/JCO.19.01154
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Pemetrexed
04Q9AIZ7NO
Carboplatin
BG3F62OND5
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Gefitinib
S65743JHBS
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-136Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn